# Long-Acting GH Stack

> Long-Acting GH Stack combines CJC-1295 DAC with Ipamorelin for sustained GHRH and ghrelin-receptor signaling across the GH and IGF-1 axis.

Canonical: https://pepflow.app/stacks/cjc-1295-ipamorelin/

Long-acting GH-axis stack pairing CJC-1295 DAC with Ipamorelin.

Anti-aging Lean mass Recovery Sleep Body composition GH pulse

[CJC-1295](<https://pepflow.app/peptides/cjc-1295/>) [Ipamorelin](<https://pepflow.app/peptides/ipamorelin/>)

## Overview

Long-Acting GH Stack pairs CJC-1295 DAC with Ipamorelin, combining a long-acting GHRH analog with a selective ghrelin-receptor growth-hormone secretagogue. The practical rationale is dual upstream stimulation of the GH/IGF-1 axis.[\[1\]](<https://pubmed.ncbi.nlm.nih.gov/16352683/>) [\[2\]](<https://pubmed.ncbi.nlm.nih.gov/17018654/>) [\[3\]](<https://pubmed.ncbi.nlm.nih.gov/9849822/>) [\[4\]](<https://pubmed.ncbi.nlm.nih.gov/10496658/>)

Because CJC-1295 DAC is designed for longer exposure, the stack is less about frequent pulse timing and more about sustained GH/IGF-1 axis stimulation plus secretagogue signaling. That changes monitoring and side-effect logic.[\[1\]](<https://pubmed.ncbi.nlm.nih.gov/16352683/>) [\[2\]](<https://pubmed.ncbi.nlm.nih.gov/17018654/>) [\[7\]](<https://pubmed.ncbi.nlm.nih.gov/41966639/>)

## Peptides in this stack

- [CJC-1295](<https://pepflow.app/peptides/cjc-1295/>) - GH/IGF axis peptide · A long-acting GHRH analog designed for sustained GH and IGF-1 signaling, with human biomarker evidence but limited outcome data. · Anti-aging Lean mass Recovery +2 · B Moderate Moderate Data

- [Ipamorelin](<https://pepflow.app/peptides/ipamorelin/>) - GH/IGF axis peptide · A selective ghrelin-receptor secretagogue with human GH pharmacology and postoperative GI trial data, but limited long-term wellness outcome evidence. · GH pulse Recovery Body composition +1 · C Preliminary Limited Data

## Why They're Combined

CJC-1295 is the GHRH-side signal: it stimulates pituitary GHRH receptors and is designed for longer GH/IGF-1 axis exposure. Ipamorelin is the ghrelin/GHS-receptor side: it triggers GH release through a separate receptor pathway with a shorter secretagogue signal.[\[1\]](<https://pubmed.ncbi.nlm.nih.gov/16352683/>) [\[2\]](<https://pubmed.ncbi.nlm.nih.gov/17018654/>) [\[3\]](<https://pubmed.ncbi.nlm.nih.gov/9849822/>) [\[4\]](<https://pubmed.ncbi.nlm.nih.gov/10496658/>)

The stack exists because those signals are complementary, not identical. One component provides sustained GHRH-side stimulation, while the other adds a more direct secretagogue push. The goal is GH-axis support, not proof of a specific body-composition or longevity outcome.[\[2\]](<https://pubmed.ncbi.nlm.nih.gov/17018654/>) [\[3\]](<https://pubmed.ncbi.nlm.nih.gov/9849822/>) For scheduling terminology, read the [peptide stack planning guide](<https://pepflow.app/blog/how-to-stack-peptides/>).

## How They Work Together

The proposed mechanism is dual upstream stimulation of the GH axis. CJC-1295 acts through the GHRH receptor and can keep GH/IGF-1 signaling elevated over a longer window. Ipamorelin acts as a ghrelin-receptor agonist that produces a shorter secretagogue signal.[\[1\]](<https://pubmed.ncbi.nlm.nih.gov/16352683/>) [\[2\]](<https://pubmed.ncbi.nlm.nih.gov/17018654/>) [\[4\]](<https://pubmed.ncbi.nlm.nih.gov/10496658/>)

That receptor split is why the stack is discussed for sleep-timed recovery and body-composition support. The same downstream monitoring issues still apply: IGF-1, glucose, edema, numbness or tingling, carpal-tunnel-like symptoms, and anti-doping status.[\[7\]](<https://pubmed.ncbi.nlm.nih.gov/41966639/>) [\[8\]](<https://ita.sport/resource/wada-2026-prohibited-list/>)

## What the Evidence Shows

CJC-1295 has human pharmacology evidence showing prolonged GH and IGF-1 stimulation. Ipamorelin has human pharmacokinetic/pharmacodynamic and postoperative-ileus development context. Those are component data, not stack-level outcome evidence.[\[1\]](<https://pubmed.ncbi.nlm.nih.gov/16352683/>) [\[2\]](<https://pubmed.ncbi.nlm.nih.gov/17018654/>) [\[4\]](<https://pubmed.ncbi.nlm.nih.gov/10496658/>) [\[5\]](<https://pubmed.ncbi.nlm.nih.gov/25331030/>)

No controlled human trial establishes that CJC-1295 plus Ipamorelin improves fat loss, muscle gain, sleep quality, recovery, or longevity outcomes compared with either component alone or with approved GH-axis care. The evidence supports receptor logic more than public outcome claims.[\[7\]](<https://pubmed.ncbi.nlm.nih.gov/41966639/>) [\[6\]](<https://www.fda.gov/media/182088/download>)

## Typical Protocol

Common CJC-1295 DAC schedules usually use 2 mg per dose, 2-3 times weekly, often before bed. Common Ipamorelin schedules use 200-300 mcg per dose, 1-3 times daily, usually away from food and often before bed or post-workout.[\[1\]](<https://pubmed.ncbi.nlm.nih.gov/16352683/>) [\[4\]](<https://pubmed.ncbi.nlm.nih.gov/10496658/>) [\[7\]](<https://pubmed.ncbi.nlm.nih.gov/41966639/>)

Many plans use an 8-12 week block before labs and symptoms are reviewed. Because DAC exposure is longer, keep CJC-1295 on fixed weekly days and track IGF-1, fasting glucose, edema, numbness or tingling, sleep quality, blood pressure, and appetite.[\[2\]](<https://pubmed.ncbi.nlm.nih.gov/17018654/>) [\[7\]](<https://pubmed.ncbi.nlm.nih.gov/41966639/>)

[Full Long-Acting GH Stack dosage guide →](<https://pepflow.app/stacks/cjc-1295-ipamorelin/dosage/>)

## Important Considerations

This stack refers to the DAC version of CJC-1295, not the short-acting no-DAC form. DAC and no-DAC patterns differ in exposure duration, timing, and practical monitoring. The specific CJC-1295 DAC plus Ipamorelin pairing also has less direct outcome evidence than the broader GHRH-plus-secretagogue mechanism.[\[1\]](<https://pubmed.ncbi.nlm.nih.gov/16352683/>) [\[2\]](<https://pubmed.ncbi.nlm.nih.gov/17018654/>)

This is an endocrine stack, so lab and symptom monitoring matter more than with cosmetic or local-repair routines. IGF-1, fasting glucose, edema, numbness or tingling, blood pressure, sleep apnea risk, and cancer history should be part of the review. Tested athletes should treat CJC-1295 and secretagogue combinations as high-risk under anti-doping rules.[\[7\]](<https://pubmed.ncbi.nlm.nih.gov/41966639/>) [\[8\]](<https://ita.sport/resource/wada-2026-prohibited-list/>) For preparation terminology, read the [mixing versus co-scheduling explainer](<https://pepflow.app/blog/can-you-mix-peptides-together/>).

## Published research 8 sources

- [Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults.](<https://pubmed.ncbi.nlm.nih.gov/16352683/>) - \[1\] · PubMed / Journal of Clinical Endocrinology and Metabolism, 2006. human clinical.

- [Pulsatile secretion of growth hormone (GH) persists during continuous stimulation by CJC-1295, a long-acting GH-releasing hormone analog.](<https://pubmed.ncbi.nlm.nih.gov/17018654/>) - \[2\] · PubMed / Journal of Clinical Endocrinology and Metabolism, 2006. human clinical.

- [Ipamorelin, the first selective growth hormone secretagogue.](<https://pubmed.ncbi.nlm.nih.gov/9849822/>) - \[3\] · European journal of endocrinology, 1998 Nov. review.

- [Pharmacokinetic-pharmacodynamic modeling of ipamorelin, a growth hormone releasing peptide, in human volunteers.](<https://pubmed.ncbi.nlm.nih.gov/10496658/>) - \[4\] · Pharmaceutical research, 1999 Sep. human clinical.

- [Prospective, randomized, controlled, proof-of-concept study of the Ghrelin mimetic ipamorelin for the management of postoperative ileus in bowel resection patients.](<https://pubmed.ncbi.nlm.nih.gov/25331030/>) - \[5\] · International journal of colorectal disease, 2014 Dec. human clinical.

- [October 29, 2024 Meeting of the Pharmacy Compounding Advisory Committee - FDA Briefing Document 4 - Ipamorelin](<https://www.fda.gov/media/182088/download>) - \[6\] · U.S. Food and Drug Administration, 2024-10-29. regulatory.

- [Safety and Efficacy of Approved and Unapproved Peptide Therapies for Musculoskeletal Injuries and Athletic Performance.](<https://pubmed.ncbi.nlm.nih.gov/41966639/>) - \[7\] · PubMed / Sports Medicine, 2026. review.

- [The 2026 List of Prohibited Substances and Methods](<https://ita.sport/resource/wada-2026-prohibited-list/>) - \[8\] · World Anti-Doping Agency, 2026. regulatory.

[PepFlow library coverage](<https://pepflow.app/research/peptide-library/#guide-coverage>)

## Quick facts

**Components**

[CJC-1295](<https://pepflow.app/peptides/cjc-1295/>) Moderate [Ipamorelin](<https://pepflow.app/peptides/ipamorelin/>) Preliminary

**Citations**

[8 sources](<https://pepflow.app/stacks/cjc-1295-ipamorelin/#published-research>)

**Updated**

Aug 17, 2026

### Potential benefits

- Anti-aging
- Lean mass
- Recovery
- Sleep
- Body composition
- GH pulse

## Related

- [CJC-1295 Peptide](<https://pepflow.app/peptides/cjc-1295/>)
- [Ipamorelin Peptide](<https://pepflow.app/peptides/ipamorelin/>)
- [How to Stack Peptides: A Practical Protocol Guide](<https://pepflow.app/blog/how-to-stack-peptides/>)
- [Long-Acting GH Stack dosage guide](<https://pepflow.app/stacks/cjc-1295-ipamorelin/dosage/>)
